Skip to main content
SpringerLink
Log in

Nivolumab cost effective for mRCC in China, not in USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

  2. three times the per-capita gross domestic product

  3. three times the per-capita gross domestic product

Reference

  • Wan XM, et al. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer : 16 Mar 2017. Available from: URL: http://doi.org/10.1002/cncr.30666

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab cost effective for mRCC in China, not in USA. PharmacoEcon Outcomes News 775, 24 (2017). https://doi.org/10.1007/s40274-017-3888-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3888-9

Search

Navigation